| Megan Zanol, CNM | |
|
94505 E Granada Ct, Kennewick, WA 99338-8894 | |
| (509) 619-5255 | |
| Not Available |
| Full Name | Megan Zanol |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 94505 E Granada Ct, Kennewick, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164201091 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | ARNP.AP.61492741-CNM (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Zanol, CNM 94505 E Granada Ct, Kennewick, WA 99338-8894 Ph: (509) 619-5255 | Megan Zanol, CNM 94505 E Granada Ct, Kennewick, WA 99338-8894 Ph: (509) 619-5255 |
News Archive
As an acoustical engineer, Craig Dolder - currently a graduate student at the University of Texas, Austin - knew that loud noises can damage hearing. Even so, when Canada's Formula 1 Grand Prix coincided with an Acoustical Society of America (ASA) meeting that he was attending in Montreal, Quebec, earlier this year, Dolder was drawn to the racetrack and the deafening roar of the Formula 1 engines.
The Wall Street Journal reports that a recent small study finds that reporting of prescription side effects increases when doctors use computerized patient records. "The study, at Massachusetts General and Brigham & Women's hospitals in Boston and sponsored by Pfizer Inc., showed a large increase in reporting of adverse events to the Food and Drug Administration once doctors used an automated tool.
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
Many people take antioxidants in the belief that they will prolong their life expectancy. However, data from 67 randomised trials that involved just under a quarter of a million people failed to support this idea, a Cochrane Systematic Review has discovered.
› Verified 7 days ago
Janice F Wilder, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 320 W 10th Ave, Suite 100, Kennewick, WA 99336 Phone: 509-586-5860 Fax: 509-586-5120 | |
Julie A Walker, CNM,FNP, ARNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 320 W 10th Ave, Suite 100, Kennewick, WA 99336 Phone: 509-586-5860 Fax: 509-586-5120 | |
Lori L Evans, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 320 W 10th Ave Ste 102, Kennewick, WA 99336 Phone: 509-221-5910 |